Typically, Vemurafenib robustly inhibits ERK signaling in BRAFV600E expressing cells such as melanoma A375 cells at 0.3 μM, whereas in SKMEL239-C4 cells a similar effect required over 10 μM (Supplementary Fig. 1a, b)11,12. This evidence concerns the gene MAPK1 and melanoma.